210 related articles for article (PubMed ID: 18509125)
1. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Michaelson MD; Iliopoulos O; McDermott DF; McGovern FJ; Harisinghani MG; Oliva E
N Engl J Med; 2008 May; 358(22):2389-96. PubMed ID: 18509125
[No Abstract] [Full Text] [Related]
2. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
Bex A; Van der Veldt AA; Blank C; Meijerink MR; Boven E; Haanen JB
Acta Oncol; 2010 May; 49(4):520-3. PubMed ID: 20105087
[No Abstract] [Full Text] [Related]
3. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
4. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy for Renal Cell Carcinoma.
Joshi R; Rawal S
JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
[TBL] [Abstract][Full Text] [Related]
6. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
7. Case records of the Massachusetts General Hospital. Case 28-2006. A 59-year-old man with masses in both kidneys.
McDougal WS; Tolkoff-Rubin NE; Michaelson MD; Mueller PR; Braaten K
N Engl J Med; 2006 Sep; 355(11):1161-7. PubMed ID: 16971723
[No Abstract] [Full Text] [Related]
8. Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
Medioni J; Cojocarasu O; Belcaceres JL; Halimi P; Oudard S
Ann Oncol; 2007 Jul; 18(7):1282-3. PubMed ID: 17675397
[No Abstract] [Full Text] [Related]
9. Sunitinib as adjuvant therapy for renal cell carcinoma.
Baker H
Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
[No Abstract] [Full Text] [Related]
10. Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report.
Messina C; Di Meglio A; Nuzzo PV; Boccardo F; Ricci F
Tumori; 2015; 101(3):e79-81. PubMed ID: 26417621
[TBL] [Abstract][Full Text] [Related]
11. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
12. A case of acute adrenal insufficiency unmasked during sunitinib treatment for metastatic renal cell carcinoma.
Yoshino T; Kawai K; Miyazaki J; Kimura T; Ikeda A; Takaoka E; Suetomi T; Oikawa T; Kojima T; Iwasaki H; Shimano H; Nishiyama H
Jpn J Clin Oncol; 2012 Aug; 42(8):764-6. PubMed ID: 22581915
[TBL] [Abstract][Full Text] [Related]
13. [Bilateral adrenal masses from renal cell carcinoma: a case report].
Shioi K; Muraoka K; Tomoda T; Yoshida M; Takase K; Kishi H; Noguchi S
Hinyokika Kiyo; 2006 Jan; 52(1):19-21. PubMed ID: 16479984
[TBL] [Abstract][Full Text] [Related]
14. [Should ipsilateral adrenalectomy be performed systematically during radical nephrectomy for renal cancer?].
Joual A; Fekak H; Rabii R; Hafiani M; el Mrini M; Benjelloun S
Ann Urol (Paris); 1999; 33(6-7):421-3. PubMed ID: 10633820
[TBL] [Abstract][Full Text] [Related]
15. Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma.
Mir-Bonafé JM; Cañueto J; Bravo J; de Unamuno P
Int J Dermatol; 2013 Nov; 52(11):1445-7. PubMed ID: 23432117
[No Abstract] [Full Text] [Related]
16. [Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
Wang C; Takeda K; Shiba M; Takayama H; Munakata S
Hinyokika Kiyo; 2016 Aug; 62(8):407-10. PubMed ID: 27624106
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
[TBL] [Abstract][Full Text] [Related]
18. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma.
Maleddu A; Pantaleo MA; Castellucci P; Astorino M; Nanni C; Nannini M; Busato F; Di Battista M; Farsad M; Lodi F; Boschi S; Fanti S; Biasco G
Tumori; 2009; 95(3):382-4. PubMed ID: 19688982
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Yoshinaga A; Kamata S
Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822
[TBL] [Abstract][Full Text] [Related]
20. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
Thibault F; Billemont B; Rixe O
J Neurooncol; 2008 Jan; 86(2):243-4. PubMed ID: 17634858
[No Abstract] [Full Text] [Related]
[Next] [New Search]
